Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Casneuf, T. (Tineke)"'
Autor:
Kaufman, J.L. (Jonathan L.), Dimopoulos, M.A. (Meletios A.), White, D.J. (Darrell J.), Benboubker, L. (Lotfi), Cook, G. (Gordon), Leiba, M. (Merav), Morton, J. (James), Takezako, N. (Naoki), Kim, K. (Kihyun), Moreau, P. (Philippe), Sutherland, H.J. (Heather J.), Magen, H. (Hila), Iida, S. (Shinsuke), Kim, J.S. (Jin Sheok), Prince, H.M. (H. Miles), Cochrane, T. (Tara), Oriol, A. (Albert), O’Rourke, L. (Lisa), Trivedi, S. (Sonali), Casneuf, T. (Tineke), Krevvata, M. (Maria), Ukropec, J. (Jon), Kobos, R. (Rachel), Avet-Loiseau, H. (Herve), Usmani, S.Z. (Saad Z.), San-Miguel, J.F. (Jesús F.)
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1111::9b16e674b3429fb429d3b9686dcdd063
https://hdl.handle.net/10171/65790
https://hdl.handle.net/10171/65790
